Dr. Eva Steiness
Chief Executive Officer
Professor Eva Steiness is a “First Mover” in Danish medicine:
The first female Dean at the Faculty of Health Science, University of Copenhagen, the first female professor in Clinical Pharmacology in Denmark (Aarhus University), the first female Senior Vice President at Lundbeck AS and the first woman on its Board of Management. Prof. Steiness, who holds an MD and a DSc in Medicine from the University of Copenhagen, also became the first female biotech entrepreneur in Denmark when she founded Zealand Pharma.
With 10 years in academia, and hands on knowledge from the Danish hospital system, a doctorate in Digoxin-clinical Pharmacology, Eva Steiness had the deep understanding of medicine that it took to revitalize Lundbecks R&D organization.
In her decade at Lundbeck AS, Prof. Steiness created a broad discovery and clinical pipeline most importantly registering and launching Cipramil® (citalopram), an antidepressant drug, that reached blockbuster status.
Danish press calls Prof. Steiness the “Mother of Cipramil.”
Prof. Steiness accomplishments at Lundbeck resulted in a successful IPO in 1999 and the company is among the top 20 listed on the Danish stock exchange today.
Prof. Steiness founded Zealand Pharma A/S in 1998 and for a decade was its CEO. Under Prof. Steiness’ leadership, a once-daily prandial GLP-1 agonist (lixisenatide) for the treatment of Type 2 diabetes was developed and licensed to Aventis (today Sanofi) in 2003. Lyxumia® (lixisenatide) was first launched into the European market in 2013. Today Zealand Pharma is listed on the Danish Stock Exchange.
Before joining SERODUS in 2010, Prof. Steiness founded Newpharma, a consultancy company, offering management support to biotech companies, capitalizing on her many years of successful entrepreneurship in the pharmaceutical and biotech industry.
Prof. Steiness listed SERODUS on the Oslo Stock Exchange in 2013.
Prof. Steiness has held a string of leadership positions among others: Chairman of the Board of Genmab, Member of the Board in several of Lundbeck’s affiliates, Member of the Board of Directors of the Oticon Foundation, Member of the Medical Research Council and Chairman of the Danish Governmental Advisory Board on Research Politics.
Chief Financial Officer
+47 959 34 199
Mr. Kvam has more than 15 years of experience as CFO in both established and early phase companies such as CellCura, Rubik Solution Group, and Factor Insurance Group. He holds a degree in Master of Science in Business and Economics from the Norwegian School of Management (BI), Certified European Financial Analyst from Norwegian School of Economics and Business Administration (NHH) and a MSc in Computer Science from The George Washington University, Washington DC, USA. Mr. Kvam is a Norwegian national and lives in Oslo.
Dr. Jürgen Langhärig
Senior Vice President Business Development
Jürgen Langhärig holds a PhD in Industrial Microbiology from the University of Tübingen, Germany and an MBA from St. Gallen University, Switzerland.
Jürgen Langhärig brings more than 30 years of international marketing and business development experience to Serodus from positions in Sandoz AG (now Novartis), Nycomed AS (now Takeda), Novo Nordisk AS and Zealand Pharma AS. Since 2008 Jürgen Langhärig was VP Business Development at Bavarian Nordic AS where he was instrumental in concluding the two major licensing deals with Big Pharma which have more than tripled Bavarian Nordic’s share price within the last 12 months.
Jürgen Langhärig is the President of the Nordic Pharma Licensing Group (NPLG) , which gathers Business Development and Licensing professionals in the Nordic Area.
Dr. Nikolai C. Brun
Senior Vice President Drug Development
Nikolai is an M.D., PhD. and associate Professor at the University of Ulm, Germany. He has several years of clinical experience in medicine: From 2000-2007 he held various positions in Clinical Development, Novo Nordisk A/S. Later he led Medical Affairs of the Genzyme Northern European organization (2007-2012) gaining experience in rare diseases, cardiac and metabolic disorders and Orphan Drugs. Lastly at Genmab (2012-2015) he led the medical department, championing the partnership with JnJ on their Daratumumab compound, successfully applying for Breakthrough Designation from the FDA, before he joined Serodus in 2015.
Dr. Torben Skarsfeldt
Vice President Project Director
Dr. Skarsfeldt is M.Sc. in Biology and D.Sc. in neurobiology from University of Copenhagen. He worked 17 years in Research and Development at Lundbeck and is co-inventor of an approved antipsychotic compound. For 6 years he was Licensing Manager and Director Business Opportunities in Copenhagen and New York. After returning to Copenhagen he gained a position as Project Director heading global core teams within depression, Alzheimer's disease and stroke. In parallel, he was employee elected member of Lundbeck's Supervisory Board for 16 years when the company grew from a Scandinavian company with 800 heads to an international pharmaceutical company with more than 5000 people. He is the Founder and CEO of Pharma Guidance, a consulting company providing services to US and EU biotech. For 3 years he was successfully supporting NuPathe Inc as Project Director to develop novel proprietary formulations. He is board member of Array Diagnostic A/S, business advisor for Genomic Expression Inc, member of Copenhagen Life Science Advisors and member of KLIFO's Drug Development Counsel. Previously, he was CEO of Phlogo ApS.